NasdaqGS:IRTCMedical Equipment
How iRhythm Technologies’ AI Partnership and Strong Q2 Sales Could Shape the Outlook for IRTC Investors
In late July 2025, iRhythm Technologies reported a significant year-on-year increase in second-quarter sales to US$186.69 million, alongside a narrower net loss and improved earnings per share, while revising its full-year 2025 revenue guidance upward to US$720 million–US$730 million.
On the same day, the company announced it would partner with Lucem Health to launch an exclusive AI-powered platform for proactively identifying undiagnosed arrhythmias in high-risk patient groups, backed by...